Protagonist Therapeutics, Inc. (PTGX) |
|
20.73 -0.28 (-1.33%)
|
03-24 16:00 |
|
Open: |
20.74 |
Pre. Close: |
21.01 |
|
High:
|
21.015 |
Low:
|
20.41 |
|
Volume:
|
933,106 |
Market Cap:
|
1,063(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:29:02 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 30 One year: 35.04 |
| Support: |
Support1: 19.08 Support2: 15.01 |
| Resistance: |
Resistance1: 25.69 Resistance2: 30 |
| Pivot: |
22.68  |
| Moving Average: |
MA(5): 21.65  MA(20): 20.97
MA(100): 12.96 MA(250): 11.46 |
| MACD: |
MACD(12,26): 1.5 Signal(9): 2 |
| Stochastic oscillator: |
%K(14,3): 55.3 %D(3): 61.4 |
| RSI: |
RSI(14): 53.3 |
| 52-week: |
High: 25.76 Low: 6.9 |
| Average Vol(K): |
3-Month: 1,670 (K) 10-Days: 1,635 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PTGX ] has closed above bottom band by 30.2%. Bollinger Bands are 137.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 13 days. This is a sign that the current trend might continue. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
21.05 - 21.19 |
21.19 - 21.31 |
|
Low:
|
20.03 - 20.23 |
20.23 - 20.38 |
|
Close:
|
20.45 - 20.72 |
20.72 - 20.93 |
|
Company Description |
|
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. |
Headline News |
Sat, 25 Mar 2023
Therapeutics for Protagonists (NASDAQ:PTGX) StockNews.com has ... - Best Stocks
Fri, 24 Mar 2023
Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by ... - MarketBeat
Tue, 21 Mar 2023
Strength Seen in Nurix Therapeutics, Inc. (NRIX): Can Its 5.7% Jump ... - Nasdaq
Mon, 20 Mar 2023
Biotechnology Value Fund L P Now Owns 9.60% of Protagonist ... - Nasdaq
Mon, 20 Mar 2023
Newsflash: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Analysts Have Been Trimming Their Revenue Forecasts - Simply Wall St
Wed, 15 Mar 2023
Protagonist Therapeutics Touts Positive Data From Bone Marrow Disorder Study - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Underperform |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
49 (M) |
| Shares Float |
38 (M) |
|
% Held by Insiders
|
1.4 (%) |
|
% Held by Institutions
|
100.4 (%) |
|
Shares Short
|
2,030 (K) |
|
Shares Short P.Month
|
1,860 (K) |
Stock Financials |
|
EPS
|
-1.92 |
|
EPS Est Next Qtl
|
-0.69 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
-2.25 |
|
Book Value (p.s.)
|
6.38 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-374.7 |
|
Return on Assets (ttm)
|
-25.2 |
|
Return on Equity (ttm)
|
-45.4 |
|
Qtrly Rev. Growth
|
0 |
|
Gross Profit (p.s.)
|
0.55 |
|
Sales Per Share
|
0.71 |
|
EBITDA (p.s.)
|
-2.66 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-103 (M) |
|
Levered Free Cash Flow
|
-55 (M) |
Stock Valuations |
|
PE Ratio
|
-10.8 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
3.24 |
|
Price to Sales
|
28.97 |
|
Price to Cash Flow
|
-9.86 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
